Liew, Yixin Lee, Winnie Hui Ling Tan, Lunyi Kwa, Andrea Lay Hoon Thien, Siew Yee Cherng, Benjamin Pei Zhi Chung, Shimin Jasmine
Published in
International Journal of Antimicrobial Agents
Healthcare resources are being diverted for the containment and control of coronavirus disease 2019 (COVID-19). During this outbreak, it is cautioned that antibiotic misuse may be increased, especially for respiratory tract infections. With stewardship interventions, the duration of antibiotic therapy and length of stay of hospitalized patients can...
Sekhavati, Ehsan Jafari, Fatemeh SeyedAlinaghi, SeyedAhmad Jamalimoghadamsiahkali, Saeidreza Sadr, Sara Tabarestani, Mohammad Pirhayati, Mohammad Zendehdel, Abolfazl Manafi, Navid Hajiabdolbaghi, Mahboubeh
...
Published in
International Journal of Antimicrobial Agents
As no specific pharmacological treatment has been validated for use in coronavirus disease 2019 (COVID-19), we aimed to assess the effectiveness of azithromycin (AZM) in these patients at a referral centre in Iran. An open-label, randomised controlled trial was conducted on patients with laboratory-confirmed COVID-19. A total of 55 patients in the ...
Padilla, Sergio Telenti, Guillermo Guillén, Lucía García, José A. García-Abellán, Javier Ding, Carolina Mora, Antonia García-Pachón, Eduardo Gutiérrez, Félix Masiá, Mar
...
Published in
International Journal of Antimicrobial Agents
This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated un...
Catteau, Lucy Dauby, Nicolas Montourcy, Marion Bottieau, Emmanuel Hautekiet, Joris Goetghebeur, Els van Ierssel, Sabrina Duysburgh, Els Van Oyen, Herman Wyndham-Thomas, Chloé
...
Published in
International Journal of Antimicrobial Agents
Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital m...
Wang, Lisheng Wang, Yiru Ye, Dawei Liu, Qingquan
Published in
International Journal of Antimicrobial Agents
Lopez, Alexandre Duclos, Gary Pastene, Bruno Bezulier, Karine Guilhaumou, Romain Solas, Caroline Zieleskiewicz, Laurent Leone, Marc
Published in
International Journal of Antimicrobial Agents
During the Covid-19 pandemic, many intensive care unit (ICU) patients received hydroxychloroquine. The primary objective of this study was to assess the effects of hydroxychloroquine according to its plasma concentration in ICU patients. A single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. A...
Davido, Benjamin Boussaid, Ghilas Vaugier, Isabelle Lansaman, Thibaud Bouchand, Frédérique Lawrence, Christine Alvarez, Jean-Claude Moine, Pierre Perronne, Véronique Barbot, Frédéric
...
Published in
International Journal of Antimicrobial Agents
Introduction The effect of anti-infective agents in COVID-19 is unclear. The impact of changes in practice on prognosis over time has not been evaluated. Methods Single center, retrospective study in adults hospitalized in a medicine ward for COVID-19 from March 5th to April 25th 2020. Patient characteristics were compared between two periods (befo...
Kara, Emre Demirkan, Kutay Unal, Serhat
Published in
International Journal of Antimicrobial Agents
Braz, Helyson Lucas Bezerra Silveira, João Alison de Moraes Marinho, Aline Diogo de Moraes, Maria Elisabete Amaral Moraes Filho, Manoel Odorico de Monteiro, Helena Serra Azul Jorge, Roberta Jeane Bezerra
Published in
International Journal of Antimicrobial Agents
Coronavirus disease 2019 (COVID-19) is a highly transmissible viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical trials have reported improved outcomes resulting from an effective reduction or absence of viral load when patients were treated with chloroquine (CQ) or hydroxychloroquine (HCQ). In addition...
Alonso, Daniel F. Farina, Hernán G.
Published in
International Journal of Antimicrobial Agents
